% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INBOOK{Perneczky:268492,
      author       = {Perneczky, Robert and Hansen, Niels and Hofmann, Anna and
                      Laske, Christoph and Priller, Josef and Grimmer, Timo and
                      Frölich, Lutz and Düzel, Emrah and Jessen, Frank and
                      Wiltfang, Jens},
      collaboration = {Group, German Network Memory Clinics- Diagnostic Tools
                      Working},
      title        = {{B}lood-{B}ased {B}iomarkers for {E}arly {A}lzheimer's
                      {D}isease {D}iagnosis in {R}eal-{W}orld {S}ettings.},
      volume       = {2785},
      address      = {New York, NY},
      publisher    = {Springer US},
      reportid     = {DZNE-2024-00238},
      isbn         = {978-1-0716-3773-9 (print)},
      series       = {Methods in Molecular Biology},
      pages        = {3 - 14},
      year         = {2024},
      comment      = {Biomarkers for Alzheimer’s Disease Drug Development /
                      Perneczky, Robert (Editor) ; New York, NY : Springer US,
                      2024, Chapter 1 ; ISSN: 1064-3745=1940-6029 ; ISBN:
                      978-1-0716-3773-9=978-1-0716-3774-6 ;
                      doi:10.1007/978-1-0716-3774-6},
      booktitle     = {Biomarkers for Alzheimer’s Disease
                       Drug Development / Perneczky, Robert
                       (Editor) ; New York, NY : Springer US,
                       2024, Chapter 1 ; ISSN:
                       1064-3745=1940-6029 ; ISBN:
                       978-1-0716-3773-9=978-1-0716-3774-6 ;
                       doi:10.1007/978-1-0716-3774-6},
      abstract     = {As our knowledge about the biology of Alzheimer's disease
                      (AD) expands and we recognize the significance of early
                      intervention for effective treatment, there is a shift in
                      focus toward detecting the disease at an early stage. AD is
                      characterized by the accumulation of misfolded amyloid-β
                      (Aβ) and phosphorylated tau proteins in the brain, leading
                      to the formation of senile plaques and neurofibrillary
                      tangles. While a definitive diagnosis of AD can only be
                      confirmed through autopsy by examining these pathological
                      features, there are now reliable methods available for
                      diagnosing the disease in living individuals. These methods
                      involve analyzing cerebrospinal fluid and using positron
                      emission tomography to accurately assess the presence of Aβ
                      and tau proteins. While these diagnostic markers have shown
                      high accuracy in memory-clinic populations, they do have
                      limitations such as the requirement for invasive lumbar
                      puncture or exposure to ionizing radiation. Additionally,
                      they are not easily accessible outside of specialized
                      healthcare settings. Blood-based biomarkers of the core
                      pathological features of AD are being developed, showing
                      promise for less invasive, scalable identification of AD
                      cases in the community. The advantages for the healthcare
                      systems of this development are obvious, but the diagnostic
                      performance of blood-based biomarkers in broader,
                      non-selected populations outside of retrospective analyses
                      and research cohorts still requires further investigation,
                      including the combination with more effective
                      neuropsychological assessments such as digital cognitive
                      test solutions.},
      keywords     = {Humans / Alzheimer Disease: cerebrospinal fluid / tau
                      Proteins: cerebrospinal fluid / Retrospective Studies /
                      Amyloid beta-Peptides: cerebrospinal fluid / Biomarkers:
                      cerebrospinal fluid / Early diagnosis of Alzheimer’s
                      disease and dementia (Other) / Early diagnosis of
                      Alzheimer’s disease and dementia (Other) / Early and
                      targeted treatment and prevention of neurodegeneration
                      (Other) / Early diagnosis of Alzheimer’s disease and
                      dementia (Other) / Patient and service user value (Other) /
                      Scalable diagnostic technologies (Other) / Subjective
                      cognitive impairment and mild cognitive impairment (Other) /
                      tau Proteins (NLM Chemicals) / Amyloid beta-Peptides (NLM
                      Chemicals) / Biomarkers (NLM Chemicals)},
      cin          = {AG Wiltfang / AG Dichgans / AG Jucker / AG Gasser / AG
                      Priller / AG Düzel / AG Jessen},
      ddc          = {570},
      cid          = {I:(DE-2719)1410006 / I:(DE-2719)5000022 /
                      I:(DE-2719)1210001 / I:(DE-2719)1210000 / I:(DE-2719)5000007
                      / I:(DE-2719)5000006 / I:(DE-2719)1011102},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 352 -
                      Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)7},
      pubmed       = {pmid:38427184},
      doi          = {10.1007/978-1-0716-3774-6_1},
      url          = {https://pub.dzne.de/record/268492},
}